Paper Details

  1. Home
  2. Paper Details

Inhaled levodopa in Parkinson's disease patients with OFF periods: A randomized 12-month pulmonary safety study.

Author: CormierJennifer, DhallRohit, GrossetDonald G, GurevichTanya, KassubekJan, OhCharles, PoeweWerner H, RascolOlivier, RudzinskaMonika, SedkovAlexander

Journal ArticleAn article published in an academic or professional journal that reports original research or scholarly analysis.
Observational StudyResearch that observes and collects data on participants' behavior and outcomes in their natural state, without intervention.
Randomized Controlled TrialA clinical trial that randomly assigns participants to treatment and control groups to evaluate the effects of an intervention.
Research Support, Non-U.S. Gov'tResearch funding provided by government agencies outside the United States.

Overview

This study evaluated the safety, including pulmonary safety, of CVT-301, an inhaled levodopa therapy for Parkinson's disease, over 12 months. The study found that CVT-301 was generally safe and well-tolerated, with no significant adverse events related to pulmonary function.
Paper Details　
Original Abstract of the Article :
CVT-301 is an orally inhaled levodopa therapy approved for the intermittent treatment of OFF episodes in Parkinson's disease patients who are taking a standard oral levodopa regimen. This open-label, randomized, controlled study over 12 months characterizes the safety, including pulmonary safety, of...See full text at original site
Dr.Camel IconDr.Camel's Paper Summary Blogラクダ博士について

ラクダ博士は、Health Journal が論文の内容を分かりやすく解説するために作成した架空のキャラクターです。
難解な医学論文を、専門知識のない方にも理解しやすいように、噛み砕いて説明することを目指しています。

* ラクダ博士による解説は、あくまで論文の要点をまとめたものであり、原論文の完全な代替となるものではありません。詳細な内容については、必ず原論文をご参照ください。
* ラクダ博士は架空のキャラクターであり、実際の医学研究者や医療従事者とは一切関係がありません。
* 解説の内容は Health Journal が独自に解釈・作成したものであり、原論文の著者または出版社の見解を反映するものではありません。


引用元：
https://doi.org/10.1016/j.parkreldis.2019.12.012

データ提供：米国国立医学図書館（NLM）

Inhaled Levodopa for Parkinson's Disease

Parkinson's disease is a progressive neurological disorder that affects movement. It can cause tremors, stiffness, and slowness of movement. This study examines the safety of inhaled levodopa, a medication used to treat Parkinson's disease.

Inhaled Levodopa for Managing Parkinson's

The study focused on CVT-301, an inhaled form of levodopa, which is used to treat "off" episodes, periods when symptoms worsen. The researchers investigated the safety of this medication, particularly its effects on the lungs. The results showed that inhaled levodopa was generally safe and well-tolerated over a 12-month period.

Navigating Parkinson's Disease

This research offers encouraging news for people with Parkinson's disease seeking alternative treatment options. Inhaled levodopa could potentially provide an effective and well-tolerated way to manage "off" episodes. It's important to remember that this is a complex condition, and individual responses to treatment can vary. Consulting with a healthcare professional is essential for determining the best course of action for your specific situation.

Dr. Camel's Conclusion

This study provides valuable information about the safety of inhaled levodopa for treating Parkinson's disease. Like a camel finding its way through a challenging desert, the quest for effective treatments for Parkinson's disease continues. Inhaled levodopa holds promise as a potential therapeutic option, offering hope for those seeking to manage their symptoms and improve their quality of life.

Date :
  1. Date Completed 2021-01-08
  2. Date Revised 2021-01-08
Further Info :

Pubmed ID

31927343

DOI: Digital Object Identifier

10.1016/j.parkreldis.2019.12.012

Related Literature

Article Analysis
・Effects of levodopa oral inhalation
SNS
PICO Info
in preparation
Languages

English

Positive IndicatorAn AI analysis index that serves as a benchmark for how positive the results of the study are. Note that it is a benchmark and requires careful interpretation and consideration of different perspectives.

This site uses cookies. Visit our privacy policy page or click the link in any footer for more information and to change your preferences.